// App-Quantinova.ai

4532 : Serum tumor marker (STM) decline rates during high-dose chemotherapy (HDCT) to predict outcome for germ cell tumor (GCT) patients (pts).

Researchers

Presenter

  • Darren Richard Feldman

Principal Investigators

  • Martin Henner Voss

  • Xiaoyu Jia

  • Lindsay Joy Van Alstine

  • Sujata Patil

  • Patricia Fischer

  • Joel Sheinfeld

  • George J. Bosl

  • Robert John Motzer

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Germ cell tumor

Biomarkers

  • Alpha-fetoprotein

  • Granulocyte colony-stimulating factor

  • Spermidine/Spermine N1-Acetyltransferase 1

Drug/Treatment

  • Carboplatin

  • Ifosfamide

  • Paclitaxel

  • Etoposide

  • Etoposide phosphate

  • Filgrastim

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved